Key Highlights
● Lilly was indicated up 2.78% at $1,411.94 after closing about 6.4% higher Thursday.
● A brokerage reiterated Buy and raised its price target to $1,497 from $1,397.
● Third-quarter Revenue rose 39% to $24.4 billion on Mounjaro and Zepbound demand.
● Full-year revenue guidance was raised to $91 billion to $92 billion.
Eli Lilly (NYSE:LLY) is adding to Thursday's big rally. The drugmaker was indicated at $1,411.94, up 2.78%, in a pre-market table as of 8:23 a.m. ET Friday. The stock closed up about 6.4% in Thursday's regular session after its third-quarter report.
The latest push comes from Wall Street. One brokerage reiterated its Buy rating and raised its price target to $1,497 from $1,397, according to market reports that published the note at 6:18 a.m. on Friday. "Eli Lilly continues to dominate the obesity market category," the brokerage wrote.
The quarter that reset expectations
To be clear on timing: Lilly's results are not new this morning. Market coverage indicates they were released on Thursday, Oct. 29, so Friday's move is follow-through plus analyst reaction.
According to a recap of Thursday's market, Lilly's third-quarter revenue rose 39% to $24.4 billion, and the company raised its full-year revenue guidance to $91 billion to $92 billion. Automated market notes attributed the growth to Mounjaro and Zepbound, its tirzepatide-based diabetes and weight-loss drugs, and said EPS beat estimates. Those notes also described the stock as at a record high, which was not independently verified.
Revenue growth of nearly 40% is unusual for a company of Lilly's size, which helps explain why analysts keep raising targets. The brokerage's new $1,497 target sits roughly 6% above Friday's pre-market indication.
Why it matters for the S&P 500
Lilly is one of the largest companies in the S&P 500 by Market Value and one of the heaviest weights in its health care sector. Its moves can therefore shift both the sector and the broader index. On Thursday, the Health Care Select Sector SPDR rose about 2.4% to a record, and a market note linked the sector's lead to Lilly's raised guidance. That helped cushion an S&P 500 that fell 0.3% as Alphabet (NASDAQ:GOOGL) posted its worst day on record.
Friday's setup looks similar. S&P 500 futures were down about 1.1% and Nasdaq-100 futures about 2.5% early in the morning after Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) results reignited worries about AI spending. Investors leaving megacap tech are looking for large companies with visible Earnings growth, and Lilly is one of the clearest examples in the market. The stock's rise also shows how concentrated health care Leadership has become, with one company's results able to lift an entire sector fund to a record.
The Fed's tightening stance matters too. With a December rate hike priced at about 85% odds after this week's meeting, according to market reports, investors are favoring companies whose earnings growth can outrun higher discount rates.
Risks and what to watch next
A stock trading near $1,400 with high growth expectations leaves little room for mistakes. Key risks include competition in obesity treatment, pricing pressure from U.S. policy changes, Manufacturing capacity, and any safety or reimbursement surprises. After a two-day surge, the stock is also more vulnerable to profit-taking if broader markets slide.
The counterargument is in the numbers: a 39% revenue jump and a higher guidance range point to Demand that is still ahead of Supply in a market that the brokerage says Lilly dominates. A higher target from a major bank the morning after the report also suggests analysts are still revising their models upward rather than chasing a stock they think has run too far.
At the open, watch whether Lilly can hold its gain as the Nasdaq trades lower, and whether other Brokers follow with higher targets. Also watch for coverage of rival obesity drugs and any pricing announcements from Washington. Lilly's fourth-quarter results and 2027 guidance will be the next major checkpoint; the date has not yet been announced.






Please wait processing your request...